LSE - Delayed Quote • GBp
Beximco Pharmaceuticals Limited (BXP.L)
At close: 5:25 PM GMT+1
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
41,651,500.24
39,266,662.24
34,669,172.05
29,493,573.87
25,611,947.66
Cost of Revenue
23,408,740.47
21,953,290.47
18,848,962.11
15,570,071.58
13,712,847.51
Gross Profit
18,242,759.77
17,313,371.77
15,820,209.95
13,923,502.29
11,899,100.15
Operating Expense
10,642,847.71
10,139,675.71
8,974,051.88
7,264,091.54
6,384,543.99
Operating Income
7,599,912.06
7,173,696.06
6,846,158.06
6,659,410.75
5,514,556.16
Net Non Operating Interest Income Expense
-1,207,383.74
-1,280,168.74
-998,780.17
-856,307.86
-993,394.79
Pretax Income
6,433,467.94
6,068,768.94
6,686,945.00
6,377,548.19
4,653,439.96
Tax Provision
1,558,923.45
1,544,300.45
1,688,316.80
1,211,798.46
1,108,956.85
Net Income Common Stockholders
4,916,418.15
4,614,066.15
5,123,136.71
5,127,693.71
3,514,687.30
Diluted NI Available to Com Stockholders
4,916,418.15
4,614,066.15
5,123,136.71
5,127,693.71
3,514,687.30
Basic EPS
11.01
10.34
11.48
11.49
7.88
Diluted EPS
11.01
10.34
11.48
11.49
7.88
Basic Average Shares
446,112.09
446,112.09
446,112.09
446,112.09
446,112.09
Diluted Average Shares
446,112.09
446,112.09
446,112.09
446,112.09
446,112.09
Total Operating Income as Reported
7,661,039.96
7,216,239.96
6,881,743.94
6,650,707.35
5,609,494.11
Rent Expense Supplemental
--
212,537.48
165,852.95
131,682.89
110,739.00
Total Expenses
34,051,588.18
32,092,966.18
27,823,013.99
22,834,163.12
20,097,391.50
Net Income from Continuing & Discontinued Operation
4,916,418.15
4,614,066.15
5,123,136.71
5,127,693.71
3,514,687.30
Normalized Income
4,908,264.91
4,606,043.67
5,159,118.83
5,142,232.38
3,543,465.17
Interest Income
--
5,529.52
3,055.36
2,377.29
20,409.29
Interest Expense
1,168,875.46
1,241,660.46
925,595.96
805,873.70
983,199.72
Net Interest Income
-1,207,383.74
-1,280,168.74
-998,780.17
-856,307.86
-993,394.79
EBIT
7,602,343.40
7,310,429.40
7,612,540.96
7,183,421.90
5,636,639.67
EBITDA
7,602,343.40
9,370,932.54
9,279,551.02
7,387,385.78
5,830,454.73
Reconciled Cost of Revenue
23,408,740.47
21,953,290.47
18,848,962.11
15,570,071.58
13,712,847.51
Reconciled Depreciation
--
2,060,503.14
1,667,010.06
203,963.89
193,815.06
Net Income from Continuing Operation Net Minority Interest
4,916,418.15
4,614,066.15
5,123,136.71
5,127,693.71
3,514,687.30
Total Unusual Items Excluding Goodwill
10,760.72
10,760.72
-48,135.29
-17,745.24
-37,490.70
Total Unusual Items
10,760.72
10,760.72
-48,135.29
-17,745.24
-37,490.70
Normalized EBITDA
7,591,582.68
9,360,171.82
9,327,686.31
7,405,131.02
5,867,945.44
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
2,607.48
2,738.25
-12,153.18
-3,206.56
-8,712.84
6/30/2020 - 10/21/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade